VERDE SCIENCE AND STERKEM GROUP SIGN PHARMACEUTICAL DEVELOPMENT
AGREEMENT
Surrey, BC - November 06, 2014 - InvestorsHub NewsWire
- (OTCPK:
VRCI) Verde Science, Inc., a Medical Research and Development
Company focused on effective treatments for emerging and
contemporary health issues, is pleased to announce that it has
executed a definitive pharmaceutical development agreement with
Sterkem Group (www.sterkempharma.com) a Mumbai,
India based pharmaceutical firm. The two companies have been
collaborating on the design of Verde Science’s research and
development plan and protocols and have agreed on principles of a
long-term association.
Under the terms of the agreement, Sterkem Group will help refine
the cannabis-based extracts identified by Verde Science’s research
and development efforts as effective for the treatment of specific
medical conditions, into deliverable and marketable pharmaceutical
formulations. The companies will share revenues from the sale
of products and licensing fees.
Harp Sangha, Verde’s CEO, explained “I am pleased to formally
add Sterkem Group to our research group. The Sterkem team is well
known to us, since we have been working closely for a long time.
The principals and researchers of Sterkem possess an array of
experience and skills that compliment Verde’s staff, and enable us
to rapidly move forward on our R&D efforts without the time and
expense of building our own back end team.”
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a
public company trading under the symbol OTCPK:
VRCI. The Company is focused on Medical Research and
Development, which includes medical marijuana research and the
development of effective treatments for emerging and contemporary
health issues.
Safe Harbor Statements?Certain information contained in this
news release constitutes "forward-looking statements" as such term
is used in applicable United States and Canadian laws. Generally,
these forward-looking statements can be identified by the use of
forward-looking terminology such as "expects" or "does not expect",
"is expected", "anticipates" or "does not anticipate", "plans",
"estimates", "intends" or "believes", or that certain actions,
events or results "may", "could", "would", "might" or "will be
taken", "occur", or "be achieved". Forward-looking statements
are based on the opinions and estimates of management as of the
date such statements are made, and are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements. Many of these factors are beyond the
Company's ability to control or predict. Important factors that may
cause actual results to differ materially and that could impact the
Company and the statements contained in this news release can be
found in the Company's filings with the SEC. Such risks and other
factors include, among others, the ability to locate and acquire
suitable interests in alternative medicine manufacturing operations
on terms acceptable to the Company, the availability of financing
on acceptable terms, accidents, labor disputes, acts of God and
other risks of the alternative medicine industry including, without
limitation, delays in obtaining governmental approvals or permits,
title disputes or claims limitations on insurance coverage. The
Company believes that the expectations reflected in the
forward-looking statements included in this news release are
reasonable; however, no assurance can be given that these
expectations will prove to be correct, and such forward-looking
statements should not be unduly relied upon. The Company assumes no
obligation to update or supplement any forward-looking statements
whether as a result of new information, future events or
otherwise.
For further information please see our investor profile available
on our website (www.verdescienceinc.com) or
contact:
Harp Sangha, Chairman/CEO
1-858-210-0236
harpsangha@shaw.ca
Louis Silver, Director of Investor Relations
1-610-710-1303
lsilver@verdescienceinc.com